CoronaryAtlas logo
CoronaryAtlas
YAP
Pathway / Endothelial activation & erosion

YAP

YAP1protein

YAP, activated downstream of JCAD, promotes endothelial dysfunction and contributes to atherosclerotic plaque instability.

Pathway placement
Cascade stepEndothelial activation & erosion
Confidencemedium
RationaleJCAD-activated pathway mediating endothelial dysfunction.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000137693

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
54
A — assay feasibility
68
E — evidence strength
37
T1DI (composite)
8
Specificity differential (R−C)-39.2
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 1
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 2
2high-demand / peri-operative stressmag 1
3sudden cardiac deathn/a
4aPCI-related periproceduralmag 1
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedn/a
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 15 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(1)